CA2777406A1 - Thiazolidinedione energy restriction-mimetic agents - Google Patents

Thiazolidinedione energy restriction-mimetic agents Download PDF

Info

Publication number
CA2777406A1
CA2777406A1 CA2777406A CA2777406A CA2777406A1 CA 2777406 A1 CA2777406 A1 CA 2777406A1 CA 2777406 A CA2777406 A CA 2777406A CA 2777406 A CA2777406 A CA 2777406A CA 2777406 A1 CA2777406 A1 CA 2777406A1
Authority
CA
Canada
Prior art keywords
benzylidene
dione
thiazolidine
methyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2777406A
Other languages
English (en)
French (fr)
Inventor
Ching-Shih Chen
Jih-Hwa Guh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Publication of CA2777406A1 publication Critical patent/CA2777406A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2777406A 2009-10-09 2010-10-11 Thiazolidinedione energy restriction-mimetic agents Abandoned CA2777406A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25004509P 2009-10-09 2009-10-09
US61/250,045 2009-10-09
US30488110P 2010-02-16 2010-02-16
US61/304,881 2010-02-16
PCT/US2010/052151 WO2011044548A1 (en) 2009-10-09 2010-10-11 Thiazolidinedione energy restriction-mimetic agents

Publications (1)

Publication Number Publication Date
CA2777406A1 true CA2777406A1 (en) 2011-04-14

Family

ID=43855337

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2777406A Abandoned CA2777406A1 (en) 2009-10-09 2010-10-11 Thiazolidinedione energy restriction-mimetic agents

Country Status (6)

Country Link
US (1) US8383656B2 (enExample)
EP (1) EP2488027A4 (enExample)
JP (2) JP5847085B2 (enExample)
CN (1) CN102638980A (enExample)
CA (1) CA2777406A1 (enExample)
WO (1) WO2011044548A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012153775A1 (ja) * 2011-05-10 2012-11-15 国立大学法人神戸大学 Ras機能阻害作用を有するチオキソチアゾリジン誘導体
WO2013148994A1 (en) * 2012-03-28 2013-10-03 The Ohio State University Research Foundation Glucose transporter inhibitors
AU2014207272A1 (en) * 2013-01-18 2015-07-30 Neal D. Andruska Estrogen receptor inhibitors
CN105315223B (zh) * 2015-11-06 2017-08-25 河南大学 一种高立体和高对映选择性噻唑烷二酮类化合物、其制备方法及应用
CN111675673B (zh) * 2020-06-22 2022-06-24 郑州大学 3，4-二羟基肉桂酸酯类衍生物及其制备方法和应用
US12150935B1 (en) 2024-04-16 2024-11-26 Imam Mohammad Ibn Saud Islamic University 3-(3-(1,3-dioxoisoindolin-2-yl) propyl)-5-(4-fluorobenzylidene) thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1003083A (en) 1961-01-21 1965-09-02 Toshiyasu Kasai Novel 4-alkoxynaphthalimides
GB962019A (en) 1961-04-12 1964-06-24 Mitsubishi Chem Ind Naphthalimide optical whitening agents
JPS4957048A (enExample) 1972-10-04 1974-06-03
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPH07116352B2 (ja) 1986-10-07 1995-12-13 三菱化学株式会社 熱可塑性ポリエステル樹脂組成物
JPS6424852A (en) 1987-07-21 1989-01-26 Mitsubishi Chem Ind Polyamide resin composition
US4965302A (en) 1988-03-29 1990-10-23 Mitsubishi Kasei Corporation Thermoplastic polyester resin composition and molded articles produced therefrom
JP2792111B2 (ja) 1989-06-16 1998-08-27 三菱化学株式会社 ポリエステル樹脂成形体の製造方法
EP0454501B1 (en) 1990-04-27 2001-09-05 Sankyo Company Limited Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides
JP3020353B2 (ja) 1992-07-21 2000-03-15 ポーラ化成工業株式会社 化粧料
US6046222A (en) 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JPH07247978A (ja) 1994-03-14 1995-09-26 Hitachi Ltd 冷媒ポンプ
GB9409466D0 (en) 1994-05-12 1994-06-29 Ciba Geigy Ag Textile treatment
DE69533417T2 (de) 1994-05-12 2005-08-18 Ciba Specialty Chemicals Holding Inc. Textilbehandlungen
US5801173A (en) 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
JP2817708B2 (ja) 1996-05-29 1998-10-30 日本電気株式会社 有機非線形光学材料及び有機非線形光学素子
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
CA2383347A1 (en) 1999-08-31 2001-03-08 Maxia Pharmaceuticals, Inc. Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
DE10353328A1 (de) 2003-11-14 2005-06-16 Basf Ag Verwendung von Naphthalin-1,8-dicarbonsäuremonoimiden
AU2005275279A1 (en) * 2004-07-14 2006-02-23 Janssen Pharmaceutica N.V. Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases
WO2006069217A2 (en) * 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule cyclin d1 ablative agents
WO2006069186A2 (en) 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
US7608715B2 (en) 2005-11-21 2009-10-27 Sabic Innovative Plastics Ip B.V. Fluorescent brighteners, methods of preparation thereof, fluorescent brightener compositions, and methods of preparation and uses thereof
CA2679944A1 (en) * 2007-03-07 2008-09-12 Janssen Pharmaceutica N.V. Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators
GB0715284D0 (en) * 2007-08-06 2007-09-12 Medical Res Council Crystal structure of ampk and uses thereof
WO2009064486A2 (en) * 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
EP2254576B1 (en) * 2008-02-22 2013-08-28 The Ohio State University Research Foundation Androgen receptor-ablative agents

Also Published As

Publication number Publication date
JP2013507397A (ja) 2013-03-04
JP2015098492A (ja) 2015-05-28
US8383656B2 (en) 2013-02-26
US20110086895A1 (en) 2011-04-14
CN102638980A (zh) 2012-08-15
WO2011044548A1 (en) 2011-04-14
EP2488027A4 (en) 2013-04-17
EP2488027A1 (en) 2012-08-22
JP5847085B2 (ja) 2016-01-20

Similar Documents

Publication Publication Date Title
Xia et al. Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets
Gao et al. Urolithin A protects against acetaminophen-induced liver injury in mice via sustained activation of Nrf2
Abe et al. TGF-β1 stimulates mitochondrial oxidative phosphorylation and generation of reactive oxygen species in cultured mouse podocytes, mediated in part by the mTOR pathway
Ren et al. Discovery of STAT3 and histone deacetylase (HDAC) dual-pathway inhibitors for the treatment of solid cancer
Weinstain et al. In vivo targeting of hydrogen peroxide by activatable cell-penetrating peptides
Wu et al. Targeting regulated cell death with pharmacological small molecules: an update on autophagy-dependent cell death, ferroptosis, and necroptosis in cancer: miniperspective
Zhou et al. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino) methyl] benzamide (MGCD0103), an orally active histone deacetylase inhibitor
Huang et al. Ethanesulfohydroxamic acid ester prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs): synthesis, nitric oxide and nitroxyl release, cyclooxygenase inhibition, anti-inflammatory, and ulcerogenicity index studies
Pan et al. Pterostilbene suppressed lipopolysaccharide-induced up-expression of iNOS and COX-2 in murine macrophages
US8383656B2 (en) Thiazolidinedione energy restriction-mimetic agents
Xia et al. Sulforaphane inhibits nonmuscle invasive bladder cancer cells proliferation through suppression of HIF-1α-mediated glycolysis in hypoxia
Xu et al. Discovery and modification of in vivo active Nrf2 activators with 1, 2, 4-oxadiazole core: hits identification and structure–activity relationship study
Park et al. Mono-(2-ethylhexyl) phthalate aggravates inflammatory response via sirtuin regulation and inflammasome activation in RAW 264.7 cells
Bae Sirtuin 6, a possible therapeutic target for type 2 diabetes
Brunetti et al. New Approaches to Cancer Therapy: Combining Fatty Acid Amide Hydrolase (FAAH) Inhibition with Peroxisome Proliferator-Activated Receptors (PPARs) Activation: Miniperspective
Zhang et al. Discovery of small molecules simultaneously targeting NAD (P) H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase: treatment of drug-resistant non-small-cell lung cancer
Wang et al. Discovery of novel anti-breast-cancer inhibitors by synergistically antagonizing microtubule polymerization and aryl hydrocarbon receptor expression
Chen et al. Antioxidant properties of novel dimers derived from natural β-elemene through inhibiting H2O2-induced apoptosis
Wang et al. Design and synthesis of novel celastrol derivative and its antitumor activity in hepatoma cells and antiangiogenic activity in zebrafish
Liu et al. Resveratrol suppresses hepatic fatty acid synthesis and increases fatty acid β-oxidation via the microRNA-33/SIRT6 signaling pathway
US9174951B2 (en) Glucose transporter inhibitors
Qin et al. Small molecule-driven LKB1 deacetylation is responsible for the inhibition of hepatic lipid response in NAFLD
Fayad et al. Novel acrylate-based derivatives: design, synthesis, antiproliferative screening, and docking study as potential combretastatin analogues
Binarci et al. Design, synthesis, and evaluation of novel Indole‐Based small molecules as sirtuin inhibitors with anticancer activities
Zhang et al. Imaging and inhibiting: a dual function molecular flare for cancer cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151008

FZDE Discontinued

Effective date: 20181203